within Pharmacolibrary.Drugs.ATC.D;

model D07AC17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.018333333333333333,
    adminDuration  = 600,
    adminMass      = 5e-05,
    adminCount     = 1,
    Vd             = 0.004200000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Fluticasone is a synthetic corticosteroid with potent anti-inflammatory properties. It is commonly used topically for the treatment of dermatological conditions such as eczema, psoriasis, and atopic dermatitis. It is widely approved and used today in multiple formulations, including creams, nasal sprays, and inhalers.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for topical administration in adults, based on literature of topical corticosteroid use, but no direct clinical PK publication for topical fluticasone found.</p><h4>References</h4><ol><li><p>Crim, C, Pierre, LN, &amp; Daley-Yates, PT (2001). A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. <i>Clinical therapeutics</i> 23(9) 1339–1354. DOI:<a href=&quot;https://doi.org/10.1016/s0149-2918(01)80113-2&quot;>10.1016/s0149-2918(01)80113-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11589253/&quot;>https://pubmed.ncbi.nlm.nih.gov/11589253</a></p></li><li><p>Roeder, A, Schaller, M, Schäfer-Korting, M, &amp; Korting, HC (2005). Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. <i>Skin pharmacology and physiology</i> 18(1) 3–11. DOI:<a href=&quot;https://doi.org/10.1159/000081680&quot;>10.1159/000081680</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15608497/&quot;>https://pubmed.ncbi.nlm.nih.gov/15608497</a></p></li><li><p>Szefler, SJ (2001). Pharmacokinetics of intranasal corticosteroids. <i>The Journal of allergy and clinical immunology</i> 108(1 Suppl) S26–S31. DOI:<a href=&quot;https://doi.org/10.1067/mai.2001.115563&quot;>10.1067/mai.2001.115563</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11449203/&quot;>https://pubmed.ncbi.nlm.nih.gov/11449203</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D07AC17;
